North America Insulin Market for Type 1 And Type 2 Diabetes Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Insulin Market for Type 1 And Type 2 Diabetes Market Size

• The North America insulin market for type 1 and type 2 diabetes market was valued at USD 8.38 billion in 2024 and is expected to reach USD 10.58 billion by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 3.0%, primarily driven by the anticipated launch of therapies
• This growth is driven by factors such as the growing prevalence of diabetes, particularly Type 1 and Type 2, drives the demand for insulin. Additionally, advancements in insulin delivery systems and the increasing adoption of personalized diabetes care

Insulin Market for Type 1 And Type 2 Diabetes Market Analysis

• Type 1 diabetes is an autoimmune condition where the body’s immune system attacks and destroys insulin-producing beta cells in the pancreas, leading to an insulin deficiency. Type 2 diabetes occurs when the body becomes resistant to insulin or doesn't produce enough. Insulin therapy is used to regulate blood glucose levels in both conditions, improving glycemic control and preventing complications like cardiovascular diseases, kidney failure, and nerve damage
• Type 1 diabetes (T1D) is typically diagnosed in childhood or adolescence and requires lifelong insulin therapy, as the pancreas produces little to no insulin. It is an autoimmune disorder where the immune system mistakenly attacks insulin-producing beta cells. Type 2 Diabetes (T2D) is more common and primarily occurs in adults, although it is increasingly seen in children due to rising obesity rates. T2D is characterized by insulin resistance, where the body does not use insulin effectively. Over time, the pancreas cannot produce enough insulin to maintain normal blood glucose levels. Both types of diabetes require regular monitoring and insulin therapy to manage blood sugar levels effectively. Insulin treatment helps in preventing long-term complications like retinopathy, neuropathy, and cardiovascular diseases, improving the overall quality of life for patients
• The U.S. stands out as one of the dominant region for Insulin Market for Type 1 And Type 2 Diabetes, driven by its advanced healthcare infrastructure and high adoption of innovative insulin delivery technologies

• For instance, U.S. continues to lead in the use of insulin pumps and continuous glucose monitoring systems, enabling better diabetes management

• With a growing focus on diabetes treatment and patient-centric solutions, the region drives significant advancements in insulin therapies, contributing greatly to North America market growth.

Report Scope and Insulin Market For Type 1 And Type 2 Diabetes Market Segmentation

Insulin Market for Type 1 And Type 2 Diabetes Market Trends

“Increased Adoption of Smart Insulin Delivery Systems”

• One prominent trend in the North America insulin market for type 1 and type 2 diabetes is the growing adoption of smart insulin delivery systems
• These advanced devices enhance diabetes management by offering real-time monitoring and insulin dose adjustments based on glucose levels, improving precision and overall treatment outcomes

• For instance, insulin pumps integrated with continuous glucose monitoring (CGM) systems allow for automated insulin delivery, adjusting doses based on real-time data, which helps maintain optimal glucose control with minimal manual intervention

• Digital platforms also facilitate seamless data tracking, enabling patients and healthcare providers to monitor trends, improve treatment plans, and prevent complications
• This trend is transforming diabetes care, promoting better patient compliance and outcomes, and driving the demand for advanced insulin delivery technologies in the market

Insulin Market for Type 1 And Type 2 Diabetes Market Dynamics

Driver

“Rising Prevalence of Diabetes”

• The increasing number of individuals diagnosed with diabetes creates a substantial demand for effective insulin therapies, which in turn drives growth in the North America insulin market. Factors such as sedentary lifestyles, unhealthy diets, and an aging population contribute to this trend, resulting in a larger patient base requiring diabetes management solutions
• The heightened need for insulin products spurs innovation and competition among pharmaceutical companies, leading to the development of new formulations and delivery methods. This dynamic environment supports existing therapies and encourages the introduction of affordable biosimilars and improved technologies, further expanding market opportunities

For instance,

• In 2024, as per WHO, the number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022. This rise was more rapid in low- and middle-income countries than in high-income countries. Diabetes caused over 2 million deaths in 2021, with significant complications like kidney failure and heart disease
• In March 2024, as per NCBI, diabetes prevalence has significantly increased, with 537 million adults affected in 2021, representing 10.5% of the population. By 2030, this number is projected to rise to 643 million (11.3%). Diabetes-related healthcare costs were $966 billion in 2021, expected to exceed $1054 billion by 2045
• The rising North America prevalence of diabetes is fueling the need for innovative and convenient treatments, which can significantly improve patient quality of life and adherence to therapy. While challenges related to bioavailability and production costs remain, the market potential is vast, offering a promising solution for both Type 1 and Type 2 diabetes management

Opportunity

“Advancements in Insulin Formulation and Delivery Technologies”

• Advancements in insulin drug formulation, including nanoparticle carriers, mucoadhesive agents, and pH-sensitive coatings, have significantly improved the bioavailability of oral insulin, making it a viable alternative to traditional injections. Innovations such as insulin analogs and smart drug delivery systems enhance absorption and enable real-time glucose monitoring. These breakthroughs address patient adherence, particularly in emerging markets with increasing diabetes prevalence, creating significant growth opportunities for the oral insulin market

For instance,

• A July 2020 article by NCBI highlighted that the urgent need for innovative treatments to address the growing diabetes burden. Key needs include improving patient adherence to treatment regimens, reducing healthcare costs, and providing effective, non-invasive solutions for diabetes management. Advancements like oral insulin and smart drug delivery systems present promising opportunities to meet these challenges and improve patient outcomes
• In August 2024, MDPI reported that advancements in drug delivery systems, such as nanoparticles and liposomes, to improve oral insulin bioavailability. These innovations offer a significant opportunity to enhance diabetes management by providing non-invasive, effective treatments. As North America diabetes rates rise, such advancements meet the increasing demand for patient-centric solutions, these advancements in drug delivery systems cater to the need for more accessible, patient-focused treatments

• The ongoing advancements in drug formulation and technology are transforming the oral insulin landscape, providing significant opportunities for better management of diabetes. Innovations in bioavailability enhancement, novel drug delivery systems, and the integration of digital health tools pave the way for oral insulin to become a reliable, non-invasive alternative to injectable therapies. As the North America diabetes epidemic continues to rise, these technological innovations not only boost patient adherence but also enable more efficient, tailored diabetes management, ultimately improving the quality of life

Restraint/Challenge

“Adverse Effects of High Dosage Of Insulin”

• High dosages of insulin can result in considerable adverse effects such as hypoglycemia, weight gain, and potential cardiovascular issues, which may discourage both patients and healthcare providers from embracing insulin therapies
• As a result, concerns over these complications can lead to greater caution in prescribing practices, ultimately hindering the expansion of the North America insulin market for Type 1 and Type 2 diabetes, as patients increasingly turn to alternative treatments or management strategies

For instance,

• In July 2023, NCBI stated that Hypoglycemia is the most common adverse effect of insulin therapy. The other adverse effects of insulin therapy include weight gain and rarely electrolyte disturbances such as hypokalemia, especially when used along with other drugs causing hypokalemia. Moreover, pain at the injection site and lipodystrophy at the injection site are the most common adverse effects of daily subcutaneous injections

• Moreover, the fear of adverse reactions from high dosages can result in increased healthcare costs due to hospitalization or the need for additional medications to manage side effects. This financial burden can limit access to insulin therapies, particularly in developing regions where healthcare resources are constrained, further contributing to a restrained North America insulin market. Increased awareness and education about these risks are essential, but they also underline the challenges the market faces in encouraging widespread adherence to insulin regimens

North America Insulin Market for Type 1 and Type 2 Diabetes Market Scope

The market is segmented on the basis type, product type, absorption site, age group, source, delivery method, gender, and distribution channel.

Insulin Market for Type 1 and Type 2 Diabetes Market Regional Analysis

“North America is the Dominant Country in the Insulin Market for Type 1 and Type 2 Diabetes”

• U.S. dominates the insulin market for type 1 and type 2 diabetes, driven by advanced healthcare infrastructure, high adoption of innovative insulin therapies, and the strong presence of leading pharmaceutical companies
• The U.S. holds a significant share due to the rising prevalence of diabetes, increased demand for advanced insulin delivery systems, and continuous innovations in diabetes management technologies
• The availability of well-established healthcare policies and robust reimbursement structures, along with substantial investments in research & development by top insulin manufacturers, further strengthens the market.
• Additionally, the growing focus on personalized diabetes care, along with an increase in the adoption of insulin pumps and continuous glucose monitoring (CGM) systems, is fueling market expansion across the region

“U.S. is Projected to Register the Highest Growth Rate”

• The U.S. is expected to witness the highest growth rate in the Insulin Market for Type 1 and Type 2 Diabetes, driven by rapid improvements in healthcare infrastructure, increasing awareness about diabetes management, and rising adoption of advanced insulin therapies
• Countries such as U.S. and Canada are emerging as key markets due to the growing aging population, which is more susceptible to diabetes-related complications
• U.S., with its advanced healthcare systems and increasing number of diabetes specialists, remains a crucial market for insulin therapies. The country continues to lead in the adoption of innovative insulin delivery devices, such as insulin pumps and continuous glucose monitoring (CGM) systems
• U.S. and Canada, with their large diabetic populations and rising rates of diabetes-related health complications, are witnessing increased government and private sector investments in modern diabetes care solutions. The expanding presence of North America insulin manufacturers and improving access to advanced diabetes treatment options further contribute to market growth

Insulin Market for Type 1 and Type 2 Diabetes Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (U.S.)
• Sanofi (France)
• Biocon (India)
• Lupin (India)
• Shanghai Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (China)
• Diasome Pharmaceuticals, Inc. (U.S.)
• SciGen Pte. Ltd. (Singapore)
• Wockhardt (India)
• MJ Biopharma Pvt. Ltd. (India)
• Oramed Pharmaceuticals (U.S.)
• Adocia (France)
• Nektar Therapeutics (U.S.)

Latest Developments in North America Insulin Market for Type 1 and Type 2 Diabetes

• In September 2024, Novo Nordisk has announced a new partnership to establish human insulin production in South Africa, strengthening its commitment to diabetes care in Africa. Currently reaching 500,000 people in Sub-Saharan Africa, this initiative aims to expand insulin access, with a goal of supplying 4.1 million people with type 1 and type 2 diabetes across the continent by 2026
• In August, Eli Lilly announced positive results from the SURMOUNT-1 study, showing that weekly tirzepatide (Zepbound/Mounjaro) reduced the risk of type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. The 15 mg dose led to a 22.9% average weight loss over 176 weeks, demonstrating sustained efficacy
• In December 2022, Sanofi expanded its collaboration with Innate Pharma, focusing on natural killer (NK) cell engagers in oncology. Sanofi licensed the B7H3-targeting NK cell engager program from Innate's ANKET platform, with the option to add two more targets. This partnership aims to develop new cancer therapies, including treatments for solid tumors, enhancing Sanofi's immuno-oncology pipeline. The collaboration is expected to provide innovative cancer treatment options with a strong safety profile, benefiting patients by offering potential therapies for multiple cancer types. Sanofi will handle further development, manufacturing, and commercialization responsibilities
• In December 2024, Lupin Acquired Huminsulin from Lilly to Enhance Diabetes Portfolio. It was performed in the aim to expand diabetes portfolio and provide high-quality, affordable health care to our patients

SKU-73778